Bosutinib: A New Kinase Inhibitor for Treatment of Philadelphia Chromosome Positive Leukemia

Researchers involved in an international study have reported that bosutinib (SKI606) is a new active kinase inhibitor for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) or acute lymphoid leukemia (ALL). The details of this study were presented at the 2007 meeting of the American Society of Clinical Oncology in June.

December 10th 2007


PORTLAND, Ore. - Oregon Health & Science University Cancer Institute researchers have found a new, experimental drug candidate it to be effective against a highly resistant mutation in chronic myeloid leukemia (CML).

Report on the 6th CML Patient and Carer Seminar held in Edinburgh on Saturday 24th November 2007

The seminar was held at Houstoun House Hotel which is just outside of Edinburgh and was hosted by Tessa Holyoake from Glasgow in collaboration with Steve O'Brien from Newcastle.

Please use this template as a basis (you can change it if you need to) for contacting your MP and making them aware of the situation regarding the proposed NICE appraisal for both Dasatinib and Nilotinib. It is crucial that as many people as possible help put pressure on the Health Dept. to go ahead with an appraisal for both of these drugs as it will ensure NHS funding and therefore access to alternative life saving therapy for Glivec resistant CML patients.

NCCN 2nd Annual Congress: Hematologic Malignancies - Update on Primary Therapy, Second-Line Therapy, and New Agents for Chronic Myelogenous Leukemia (Slides with Audio) CME/CE
Jerald P. Radich, MD

Please click on the link below to download a list of the centres that are open and recruiting.

On 20 September 2007 the CHMP
(Committee for Medicinal Products for Human Use)
of the EMEA
(European Medicines Evaluation Agency) adopted a positive opinion towards Tasigna and recommended to grant a marketing authorisation for the drug at 200 mg, hard capsule for CML with intolerance or resistance against Gleevec.

" Bristol-Myers Squibb is pleased about the approval of the 100mg once-daily stating dose of Sprycel for chronic phase patients..... The clinical data on the new starting dose demonstrate improved patient tolerability whilst maintaining efficacy compared to the previous starting dose of 70mg twice daily," said Frank Pasqualone, General Manager, Bristol-Myers Squibb UK.

The Health-EU Portal started issuing last week a multilingual newsletter, which aims to better inform European citizens on what is going on in the field of health at European and international level.

Chronic myeloid leukaemia (CML) can be considered as a paradigm for neoplasias that evolve through a multi-step process. CML is also one of the best examples of a disease that can be targeted by molecular therapy; however, the success of new 'designer drugs' is largely restricted to the chronic phase of the disease. If not cured at this stage, CML invariably progresses and transforms into an acute-type leukaemia undergoing a 'blast crisis'. The causes of this transformation are still poorly understood. What mechanisms underlie this progression, and are they shared by other common cancers?